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Abstract
Background: Some chemicals, including some phthalate plasticizers, have been shown to have an
adjuvant effect in mice. However, an adjuvant effect, defined as an inherent ability to stimulate the
humoral immune response, was only observed after exposure to a limited number of the
phthalates. An adjuvant effect may be due to the structure or physicochemical characteristics of
the molecule. The scope of this study was to investigate which molecular characteristics that
determine the observed adjuvant effect of the most widely used phthalate plasticizer, the di-(2-
ethylhexyl) phthalate (DEHP), which is documented as having a strong adjuvant effect. To do so, a
series of nine lipophilic compounds with structural and physicochemical relations to DEHP were
investigated.
Results:  Adjuvant effect of phthalates and related compounds were restricted to the IgG1
antibody formation. No effect was seen on IgE. It appears that lipophilicity plays a crucial role, but
lipophilicity does not per se cause an adjuvant effect. In addition to lipophilicity, a phthalate must
also possess specific stereochemical characteristics in order for it to have adjuvant effect.
Conclusion: The adjuvant effect of phthalates are highly influenced by both stereochemical and
physico-chemical properties. This knowledge may be used in the rational development of
plasticizers without adjuvant effect as well as in the design of new immunological adjuvants.
Background
Exposure to immunomodulatory environmental pollut-
ants can promote development of allergy as reviewed by
Nielsen et al. [1]. However, immunomodulation is also
used intentionally to promote the efficacy of vaccines [2].
Phthalates, which are added for example to poly vinyl
chloride (PVC) plastic polymers in order to increase the
flexibility of the product, constitute a group of xenobiotics
that have been in focus regarding their effect on the
immune system. Phthalates are not themselves immuno-
genic [3], but phthalate plasticizers and metabolites
hereof have been shown to enhance the effect of immuno-
gens, which means they have an adjuvant effect [4-7].
Also, it has been suggested that phthalates play a role in
the elicitation phase of allergy [8,9]. However, recent
long-term animal studies have not confirmed an allergy
(IgE) promoting effect of di-(2-ethylhexyl) phthalate
(DEHP) or its main metabolites, mono-2-ethylhexyl
phthalate (MEHP) [6,7]. Phthalate plasticizers with
closely related structures showed marked variability in
inducing production of specific IgG1 to a simultaneously
administered allergen in mice [5,10,11]. Whether this var-
iability to exert an adjuvant effect is due to lipophilicity,
length of the ester chains in the phthalate or due to stere-
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ochemical characteristics is not clear. The aim of this study
is twofold; a) to identify factors that contribute to the
adjuvant effect of phthalate plasticizers with the view to
enabling the design of compounds without adjuvant
effect, and b) to allow development of compounds with
maximum IgG1 promoting effects as they may be useful
as lead compounds for vaccine adjuvants. The com-
pounds included in this study are shown in Figure 1.
Methods
Animals
Inbred BALB/cJ female mice, 6–7 weeks old, were pur-
chased from Bomholtgård Breeding and Research Centre,
Denmark. The mice were randomly divided into groups of
10 to 12 and were housed in environmentally enriched
polypropylene cages (425 × 266 × 150 mm) with pine-
wood sawdust bedding (Lignocel S8, Brogaarden, Den-
mark). The mice were kept in pathogen limited conditions
and were allowed to acclimatize two weeks before immu-
nization. At the time of immunization, the mean weight
of the animals was 18 g with a SD of 1.6 g. The photope-
riod was from 7 a.m. to 7 p.m., and the temperature and
relative humidity in the animal room were 21 ± 2°C and
50 ± 5%, respectively. The cages were sanitized twice
weekly. Mice were maintained on an ovalbumin (OVA)
free diet (Altromin no. 1324, Christian Petersen, Den-
mark) and tap water was available ad libitum. Treatment of
the animals followed procedures approved by The Animal
Experiment Inspectorate, Denmark.
Chemicals
Polyethylene glycol 400 (PEG, CAS 25322-68-3, Ph. Eur.)
was purchased from Merck, Germany. Di-(2-ethylhexyl)
phthalate (DEHP, CAS 117-81-7, purity ≥ 97%) was from
Fluka, Buchs, Germany. Methyl hexadecanoate (MP, CAS
112-39-0, purity ≥ 99%) was from ABCR, Karlsruhe, Ger-
many. Tri-(2-ethylhexyl) trimellitate (TOTM, CAS: 3319-
31-1, purity ≥ 99%) and bis-(2-ethylhexyl) terephthalate
(DOTP, CAS 6422-86-2, purity ≥ 96%) were both from
Aldrich Chemical Company, Milwaykee, USA).
Butyl dodecyl phthalate is not commercially available but
was synthesized at our laboratory as follows: 600 mg (1
molequivalent) of mono-n-butyl phthalate (CAS 131-70-
4, purity>95%) synthesized at our laboratory according to
[4] was dissolved in 10 mL acetone. To this mixture was
added 223.8 mg (0.6 molequivalent) potassium carbon-
ate. Furthermore 759 mg (= 0.95 molequivalent) of
dodecyliodide (CAS 4292-19-7, purity ≥ 98% from Fluka,
Buchs, Germany) was dissolved in 15 mL acetone and
added to the monobutyl phthalate solution over a period
of approximately 25 minutes (dripping from a burette)
under continuous stirring.
As the synthesis included light sensitive chemicals, the
reaction was carried out in the dark. The mixture was
stirred for 24 hours to let the reaction complete. The mix-
ture was filtered to remove excess K2CO3 and rotary evap-
orated. The residue was extracted with diethylether and
the combined, yellow-colored ether phase was rotary
evaporated leaving a pale yellow oil. The oil was dissolved
in ether and purified by shaking it with saturated
NaHCO3. The ether phase was dried with Na2SO4, filtered
and vacuum evaporated. The final yield was 350 μL. The
identity of the butyldodecyl phthalate was confirmed by
proton nuclear magnetic resonance (1HNMR) spectros-
copy. The purity of the product was more than 95% as
determined by gas chromatography – mass spectroscopy
(GC-MS) analysis. Impurities included dodecyl iodide
and dibutyl phthalate.
Immunization procedure
Mice were sensitized intraperitoneally (i.p.) by a standard
low-dose protocol with the model allergen hen egg OVA
(grade V from Sigma, St. Louis) alone or together with one
of the test substances, which are shown in Figure 1. The
OVA control mice were given 1 μg OVA in 50 μL solvent
(vehicle), composed of sterile PEG 400, ethanol 99.9%
and sterile water in a ratio of 494:5:1. As DEHP has previ-
ously been shown to have an adjuvant effect [10], it was
used as a positive adjuvant control and reference sub-
stance. Mice in the test groups were given 1 μg OVA
together with one of the test substances, using the same
solvent as for the OVA and DEHP control groups. The
respective concentrations of the test substances were 20
μg/mL, 200 μg/mL and 2000 μg/mL. As PEG 400 may
have a mild immuno-suppressive effect [12], no more
than 50 μL was administered to each animal leading to
respective doses of test substance of 1, 10 and 100 μg per
animal. After primary immunization, the animals were
given one or two booster injections i.p. with 0.1 μg OVA
in 100 μL 0.9% saline without test compound. The first
booster injection was given 14 days after primary immu-
nization, the second booster seven days later.
Blood was collected 14 days after the respective booster
injections, i.e. day 28 and 35. Before collection of blood
by heart puncture, the mice were anaesthetized with Hyp-
norm® (fentanyl citrate 0.315 mg/ml and fluanisone 10
mg/mL from Janssen Pharma) and Dormicum® (mida-
zolam 5 mg/mL from Roche) each diluted 1:1 in sterile
water and then mixed. A volume of 125 μL per mouse was
injected s.c. in the neck region. The blood samples were
centrifuged at 2500 × g for 10 min and the serum was
stored at -80°C until analyzed.
Determination of OVA-specific antibodies in sera
Levels of OVA-specific IgE, IgG1 and IgG2a antibodies
were assessed as previously described [11].BMC Immunology 2008, 9:61 http://www.biomedcentral.com/1471-2172/9/61
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2-d structures of the studied compounds Figure 1
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Statistical analysis and evaluation of adjuvant effect
For compounds that were tested at different times, new
OVA control groups were included. This was done to nor-
malize for possible time-dependent variations in the OVA
control groups and differences in the protocols (cf.
below). Antibody levels in test groups were compared to
the corresponding OVA control group. The adjuvant
effects of the tested substances were assessed by the induc-
tion of OVA-specific IgE, IgG1 and IgG2a.
The OVA control group and the three exposure groups (1,
10 and 100 μg) were first evaluated by means of the
Kruskal-Wallis test. If significant differences were
obtained, the exposure groups were then pair-wise com-
pared to the OVA control group by means of Mann Whit-
ney's U-test.
Minitab Statistical Software, Release 13.1 Xtra (Minitab
Inc.), was used for the Kruskal-Wallis and the Mann-Whit-
ney's U-tests. P-values less than 0.05 were considered sta-
tistically significant.
The adjuvant effect was expressed as the fold increase in
the antibody production compared to the production in
the corresponding OVA control group that received the
same number of boosters (Table 1). The number of fold
increases in antibody response is called the adjuvant fac-
tor throughout this article. To increase the amount of data
used for the structure-activity relationship, data from pre-
vious studies [5,11] were included. These compounds
(dibutyl phthalate, benzyl butyl phthalates, di-n-octyl
phthalate, di-iso-nonyl phthalate and di-iso-decyl phtha-
late, cf. Table 1) were tested at slightly different condi-
tions. With regard to the previously determined data, less
time elapsed between booster injections in the immuniza-
tion protocol as well as between the last booster injection
until the collection of serum cf. [5]. In addition, the site of
injection was subcutaneous in the neck region and not i.p.
injection. The change of injection site was done to avoid
skin irritation induced by the PEG-based vehicle. The
immunization protocol was changed, as experiments per-
formed in our laboratory showed that extension of the
time periods lead to a protocol that was more robust and
superior at revealing an adjuvant effect [13]. DEHP as well
as Al(OH)3 were tested in both sensitization protocols,
and it was found that the new protocol gave rise to a 6-
fold higher IgG1 adjuvant factor with both compounds
and thus can be used as a conversion factor. Thus, to ena-
ble comparison between our previously reported data and
the data obtained in this study, the previous adjuvant fac-
tors were multiplied by a factor of 6.
As all test compounds showed maximal adjuvant effect at
the highest dose (cf. Results), this dose was used for the
description of structure-activity relationships.
Results
Systemic effect
A decrease in body weight may be used as an indicator of
general toxicity [14]. The body weights of the animals
were therefore determined before and 24 hours after pri-
mary immunization. No dose-dependent change in body
weight was observed in any of the test groups when these
were compared to the OVA control groups. This indicates
that no general toxic effects occurred after a single s.c.
injection with up to about 5 mg/kg of the studied com-
pounds.
Table 1: Adjuvant effect of test compounds based on the IgG1 levels.
Compound Adjuvant factora (dose of test compound)
1 booster 2 boosters
1: Di-n-butyl phthalate NDb 24 (10 μg)c
2: Benzyl butyl phthalate 1d 1d
3: Di-(2-ethylhexyl) phthalate (DEHP) 13 (10 μg)
33 (100 μg) 61 (100 μg)
4: Butyldodecyl phthalate (BDP) 20 (10 μg)
14 (100 μg) 68 (100 μg)
5: Di-n-octyl phthalate ND 61 (100 μg)c
6: Bis-(2-ethylhexyl) terephthalate (DOTP) 1 4 (100 μg)
7: Diisononyl phthalate ND 42 (both 10 and 100 μg)c
8: Diisodecyl phthalate ND 1c
9: Trioctyl trimellitate (TOTM) 1 1
10: Methylpalmitate (MP) 1 1
a) Adjuvant factor taken as the ratio between the IgG1 level in the test group and the OVA control group.
b) ND: Not defined, as the median IgG1 value in the OVA control group was zero.
c) Data are calculated from reference 5. Cf. 'Material and Method' for details.
d) Data are calculated from reference 11. Cf. 'Material and Method' for details.BMC Immunology 2008, 9:61 http://www.biomedcentral.com/1471-2172/9/61
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IgG1 responses
For DEHP an adjuvant factor of 33 (i.e. a 33-fold increase
in the antibody level compared to the OVA control group)
was observed in mice given 100 μg DEHP and boosted
once. After two boosters this adjuvant factor increased to
61. Administration of 10 μg DEHP did not give rise to an
adjuvant effect after one booster, but when boosted twice,
the DEHP group had a level of IgG1 that was 13 times that
of the OVA control group (cf. Table 1).
Comparable levels were seen for BDP, where an adjuvant
factor of 14 was observed after 100 μg BDP and one
booster. After two boosters, adjuvant factors increased to
68. No adjuvant effect was seen in mice given 10 μg BDP
and boosted once. After two boosters, this dose of BDP
gave rise to an adjuvant factor of 20 (cf. Table 1).
DOTP gave rise to markedly lower response; no effect was
seen after one booster whereas after two booster injec-
tions, an adjuvant factor of 4 was seen after administra-
tion of 100 μg. TOTM did not show any adjuvant effect in
the present bioassay. Neither did MP, which was included
as an example of a simple alkyl ester, exhibit an adjuvant
effect, which is in agreement with a long-term inhalation
study [15].
Data from previously tested substances were modified
according to the methods described in the M&M section
and the data are included in Table 1.
IgE and IgG2a responses
No adjuvant effects were seen on IgE, neither after one or
two booster injections for any of the studied compounds.
However, the BALB/cJ mouse strain tend to respond with
high levels of IgE after exposure to OVA and Al(OH)3, e.g.
[16].
Similarly, the production of IgG2a antibodies was absent
or low in all the control groups and test groups, suggesting
the absence of a T helper cell type 1 (Th1) response. Only
about 12% of the animals responded with a detectable
IgG2a level and the mean level of the responders was 79
arbitrary units. However, the mouse strain is capable of
responding with high IgG2a levels after OVA exposure.
Thus, animals treated with 10 μg OVA and 250 μg of the
Th1 adjuvant dimethyldioctadecyl ammonium bromide,
cf. [17] and boosted twice with 1 μg OVA in saline,
showed a mean IgG2a level of 30,000 arbitrary units (data
not shown). Overall, this study demonstrates that the
phthalates did not cause isotype switch to production of
IgE and IgG2a under the conditions of the test.
Discussion
Phthalate isomers were studied for their adjuvant effect at
different dose levels to obtain information about struc-
ture-activity relationships. The different phthalate isomers
showed a pronounced variability in enhancing the immu-
nogenicity of OVA. An adjuvant effect was seen as an abil-
ity to increase the serum level of OVA-specific IgG1
antibodies, whereas no or limited effects were seen on the
production of IgE and IgG2a, fully in line with previous
studies [5,7,18].
A number of molecular characteristics play a role for the
adjuvant activity. These include:
Lipophilicity and chain length of the ester groups
For the phthalates, the lipophilicity apparently plays an
important role for their adjuvant effect. Lipophilicity
increases with the number of carbon atoms in the mole-
cule, which suggests an optimum lipophilicity for adju-
vant effect at about the lipophilicity of DEHP (Table 1).
This is for example substantiated by the absence of adju-
vant activity of TOTM. TOTM contains, like DEHP, two
vicinal 2-ethylhexyl esters (cf. Fig 1), but TOTM has, in
contrast to DEHP, a third 2-ethylhexyl ester, which
increases the lipophilicity. However, the adjuvant effect is
not caused by the lipophilicity per se, as DOTP, which has
the same lipophilicity as DEHP and BDP, has a weak adju-
vant effect compared to DEHP and BDP. Furthermore, the
non-phthalate substance MP, which has a lipophilicity
comparable to DEHP and DBP, had no adjuvant effect.
The lack of adjuvant effect of MP is in accordance with a
recently published long-term inhalation study [15].
As previously reported, phthalates with 8 carbon atoms in
each of the 2 ester groups (a total of 16 carbon atoms)
have the maximum adjuvant effect [5]. However, the 16
carbon atoms may be unequally distributed in the ester
groups of the phthalate without affecting its adjuvant
property. Thus, BDP with chain lengths of 4+12 carbon
atoms has an adjuvant effect comparable to that of DEHP
with 8+8 carbon atoms. Also, whether the ester chain is
branched as in DEHP or linear as in DnOP does not seem
to alter the adjuvant effect of the phthalate.
Distance between the two ester groups
Whether the phthalate is an ortho or a para di-substituted
benzene plays a crucial role for the adjuvant effect. Thus
adjuvant activity virtually disappears when moving an
ester group from the ortho (2') position to the para (4')
position as seen from a comparison of DEHP and DOTP
(Fig 1 and Table 1).
In conclusion, the adjuvant activity of phthalates depends
not only on the lipophilicity but also on the stereochem-
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Conclusion
The present study provides information about structure-
activity relationship on the adjuvant effect of DEHP-
related phthalates and allows a relative comparison of
their potencies. Our study shows that even a minor alter-
ation in the structure of a phthalate has dramatic conse-
quences for the adjuvant activity, which allow design of
compounds without adjuvant effect but still being useful
as plasticizers. Also, as compounds with adjuvant effect
caused a strong IgG1 response but no isotype switch to IgE
production, it is tempting to speculate whether some of
these compounds, after a thorough safety assessment,
may have a potential as future vaccine adjuvants.
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